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Editorial: The challenge of off-label prescribing 
Before medications can be prescribed, pharmaceutical companies must apply for approval from their 
relevant government authority. Yet prescribing a medication outside of its registration (licensed) or 
off-label prescribing (unlicensed use) is not illegal, and common in palliative care. The practice has 
emerged because many symptom management guidelines are not evidence based and often include 
recommendations for the administering of medication outside of their registered use. As a result, 
prescribing off-label medications has become widespread and normalised in many palliative care 
services. It is estimated that up to a quarter of all prescriptions for licensed drugs in palliative care 
are being used for unlicensed indications or are administered by an unlicensed route (Pavis and 
Wilcock, 2001).  
An Australian and New Zealand survey of palliative care physicians’ (n=105) off-label prescribing 
practices found the majority (89%) were not aware of their palliative units having a policy requiring 
patient consent for off-label prescribing. Half (50%) correctly identified licensed medication drugs 
being provided for unlicensed use (To et al, 2013). A quarter of these physicians neither documented 
the rationale for off-label prescribing nor obtained informed consent from patients. Most (70%) 
indicated their organisation did not restrict unlicensed prescribing. Similarly, a UK study found that 
even fewer services had an off-label prescribing policy (2%) (Pavis and Wilcock, 2001). This study also 
noted there was minimal documentation in the patient’s medical records of the rationale for 
prescribing unlicensed medications, or evidence of written or verbal consent being obtained from 
the palliative care patient or their substitute decision-maker. These studies highlight the importance 
of palliative care services establishing policies to guide off-label prescribing.  
The management of common symptoms experienced by patients with advanced illness has evolved 
rapidly, with several completed randomised control trials investigating the effectiveness of 
commonly used off-licence medications. Using ketamine as an example, a trial found that this 
medication, as an adjunct to opiates and co-analgesics for cancer pain, did not have a net clinical 
benefit. In fact, the number of patients needed to treat for one additional patient to have a positive 
outcome from ketamine was 25 (95% CI, six to∞) (Hardy et al, 2012). Regular monitoring identified 
that patients experienced unnecessary adverse side-effects. While these results have not been 
universally welcomed and need to be replicated, they raise a number of clinical and ethical 
considerations for palliative care nursing practice.  
If we are truly committed to not causing harm, and minimising suffering and discomfort at the end 
of life, then we need to rethink our acceptance of administering unlicensed medications and work 
towards ensuring that the symptom management we provide is always grounded in the best 
available evidence. If we are to ensure that the care we provide is clinically, legally and ethically 
sound and justified, we need to be prepared to challenge the ongoing prescribing of these 
medications, especially where new evidence does not support their ongoing use, and seek consent 
from our patients or their substitute decision-maker before these medications are prescribed and 
administered.  
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